Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib Meeting Abstract


Authors: Diamond, E. L.; Yabe, M.; Petrova-Drus, K.; Rosenblum, M.; Rotemberg, V.; Lacouture, M. E.; Rampal, R.; Francis, J.; Knoerzer, D.; Kreider, B.; Abdel-Wahab, O. I.; Durham, B. H.
Abstract Title: Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib
Meeting Title: 2022 ASCO Annual Meeting
Journal Title: Journal of Clinical Oncology
Volume: 40
Issue: 16 Suppl.
Meeting Dates: 2022 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2022-06-01
Language: English
ACCESSION: WOS:000863680304039
PROVIDER: wos
DOI: 10.1200/JCO.2022.40.16_suppl.e19081
Notes: Meeting Abstract: e19081 -- This meeting was also held virtually -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Mario E Lacouture
    457 Lacouture
  2. Jasmine Helen Francis
    257 Francis
  3. Marc Rosenblum
    424 Rosenblum
  4. Raajit Kumar Rampal
    339 Rampal
  5. Eli Louis Diamond
    203 Diamond
  6. Benjamin Heath Durham
    115 Durham
  7. Mariko   Yabe
    51 Yabe
Related MSK Work